Non-Alcoholic Fatty Liver Disease (NAFLD) and its more severe form, Non-Alcoholic Steatohepatitis (NASH), are contributing to the growing cases of advanced liver disease in Canada and around the world. Linked to obesity and diabetes, NAFLD and NASH are increasingly recognized as indicators of metabolic syndrome, a term that refers to the cluster of conditions linked to increased cardiovascular risk. The buildup of fat in the liver can lead to liver cell injury and inflammation, which over time can lead to fibrosis, cirrhosis, liver cancer, liver failure, and the need for a liver transplant.

With NAFLD being strongly associated with the chronic disease of obesity, research has consistently shown that losing approximately 10% of your body weight causes liver enzymes to improve, which correlates with a reduction in the liver inflammation caused by the extra fat.

Developing treatments for NAFLD and NASH has proved challenging. Several drugs that appeared promising in early studies did not show significant benefits in larger clinical trials. With no approved therapies, management currently relies on lifestyle changes, such as exercise, healthy eating, and weight loss.

Health Canada recently approved a new medication, Semaglutide (brand name Wegovy), as an effective treatment for obesity. As new, effective and innovative treatments become available, it is important to understand patient experiences with these treatments and how they compare to what is already available. In collaboration with Obesity Canada, the Canadian Liver Foundation is interested in gaining the insights and perspectives of individuals who have had experience with obesity medications. If you have a few moments to spare to answer a short survey, we’d love to hear from you.